A Phase 4 interventional study of mycophenolate mofetil [CellCept] and Tacrolimus in Liver Transplantation, sponsored by Hoffmann-La Roche. Completed at 46 sites in 2 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2010-08-03.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This two-arm study will assess the efficacy and safety of a long-term calcineurin inhibitor-free maintenance regimen with CellCept and sirolimus in recipients of an orthotropic liver transplant. Patients will be randomized to receive either CellCept 1-1.5 g twice daily (BID) + tacrolimus + cyclosporine, or CellCept 1-1.5 g BID + sirolimus. The anticipated time on study treatment is 1 to 2 years, and the target sample size is 100 to 500 individuals.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: mycophenolate mofetil [CellCept] · Drug: Tacrolimus · Drug: Cyclosporine
Drug: mycophenolate mofetil [CellCept] · Drug: Sirolimus
1-1.5 g orally or intravenously twice daily
As prescribed, for 12 months
As prescribed, for 12 months
2-4 mg orally once daily for 9-11 months
Change From Baseline in Glomerular Filtration Rate (GFR) at 12 Months Posttransplant
Mean percent change from baseline in estimated glomerular filtration rate (GFR) calculated by modification of diet in renal disease (MDRD)-6 variable equation at 12 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.
Time frame: 12 months posttransplant
Change From Baseline in Glomerular Filtration Rate (GFR) at 6 Months Posttransplant
Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.
Time frame: 6 months posttransplant
Change From Baseline in Glomerular Filtration Rate (GFR) at 24 Months Posttransplant
Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.
Time frame: 24 months posttransplant
Change From Baseline in Creatinine Clearance
Mean percent change from baseline in calculated creatinine clearance (CL) at 6, 12, and 24 months posttransplantation
Time frame: 6, 12, and 24 months posttransplantation
Patients were recruited from 43 study centers in the US and Canada over a period of 3 years (24-Aug-05 to 03-Jul-08)
| Milestone | CellCept + CNI (Tacrolimus or Cyclosporine) | CellCept + Sirolimus |
|---|---|---|
| Started | 145 | 148 |
| Completed | 96 | 82 |
| Not completed | 49 | 66 |
Mean percent change from baseline in estimated glomerular filtration rate (GFR) calculated by modification of diet in renal disease (MDRD)-6 variable equation at 12 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.
| Percent change in GFR (mL/min) | CellCept + CNI (Tacrolimus or Cyclosporine) | CellCept + Sirolimus |
|---|---|---|
| Change From Baseline in Glomerular Filtration Rate (GFR) at 12 Months Posttransplant | 1.2 ± 39.86 | 19.7 ± 40.64 |
Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.
| Percent change in GFR (mL/min) | CellCept + CNI (Tacrolimus or Cyclosporine) | CellCept + Sirolimus |
|---|---|---|
| Change From Baseline in Glomerular Filtration Rate (GFR) at 6 Months Posttransplant | 1.1 ± 24.39 | 25.5 ± 45.82 |
Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.
| Mean percent change in GFR (mL/min) | CellCept + CNI (Tacrolimus or Cyclosporine) | CellCept + Sirolimus |
|---|---|---|
| Change From Baseline in Glomerular Filtration Rate (GFR) at 24 Months Posttransplant | -8.6 ± 43.37 | 13.5 ± 49.17 |
Mean percent change from baseline in calculated creatinine clearance (CL) at 6, 12, and 24 months posttransplantation
| Percent change in creatinine CL (mL/min) | CellCept + CNI (Tacrolimus or Cyclosporine) | CellCept + Sirolimus |
|---|---|---|
| 6 months | -1.3 ± 23.71 | 18.5 ± 39.93 |
| 12 months | -3.0 ± 35.86 | 14.0 ± 35.16 |
| 24 months | -12.8 ± 41.64 | 7.9 ± 44.36 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CellCept + CNI (Tacrolimus or Cyclosporine) | — | 65/146 (44.5%) | 134/146 (91.8%) |
| CellCept + Sirolimus | — | 67/148 (45.3%) | 141/148 (95.3%) |
| Event | CellCept + CNI (Tacrolimus or Cyclosporine) | CellCept + Sirolimus |
|---|---|---|
| Hepatitis CInfections and infestations | 10/146 | 8/148 |
| PyrexiaGeneral disorders | 1/146 | 7/148 |
| Renal FailureRenal and urinary disorders | 5/146 | 0/148 |
| Incisional HerniaInjury, poisoning and procedural complications | 4/146 | 4/148 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 4/146 | 0/148 |
| HyperkalaemiaMetabolism and nutrition disorders | 4/146 | 0/148 |
| CholangitisHepatobiliary disorders | 0/146 | 4/148 |
| AnaemiaBlood and lymphatic system disorders | 1/146 | 4/148 |
| Deep Vein ThrombosisVascular disorders | 2/146 | 4/148 |
| PneumoniaInfections and infestations | 3/146 | 2/148 |
| Event | CellCept + CNI (Tacrolimus or Cyclosporine) | CellCept + Sirolimus |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 42/146 | 37/148 |
| HeadacheNervous system disorders | 24/146 | 38/148 |
| LeukopeniaBlood and lymphatic system disorders | 21/146 | 35/148 |
| Oedema PeripheralGeneral disorders | 17/146 | 27/148 |
| Abdominal PainGastrointestinal disorders | 26/146 | 21/148 |
| FatigueGeneral disorders | 23/146 | 26/148 |
| RashSkin and subcutaneous tissue disorders | 5/146 | 26/148 |
| PyrexiaGeneral disorders | 21/146 | 25/148 |
| NauseaGastrointestinal disorders | 23/146 | 19/148 |
| Hepatitis CInfections and infestations | 23/146 | 20/148 |
| Age Continuous(years) | CellCept + CNI (Tacrolimus or Cyclosporine) | CellCept + Sirolimus | Total |
|---|---|---|---|
| Mean | 53.4 ± 7.88 | 53.2 ± 8.83 | 53.3 ± 8.36 |
| Sex: Female, Male(Participants) | CellCept + CNI (Tacrolimus or Cyclosporine) | CellCept + Sirolimus | Total |
|---|---|---|---|
| Female | 35 | 38 | 73 |
| Male | 110 | 110 | 220 |
| Race/Ethnicity, Customized(participants) | CellCept + CNI (Tacrolimus or Cyclosporine) | CellCept + Sirolimus | Total |
|---|---|---|---|
| American Indian | 3 | 4 | 7 |
| Asian or Pacific Islander | 3 | 11 | 14 |
| Black | 11 | 8 | 19 |
| White | 126 | 125 | 251 |
| Other | 2 | 0 | 2 |
| Height(cm) | CellCept + CNI (Tacrolimus or Cyclosporine) | CellCept + Sirolimus | Total |
|---|---|---|---|
| Mean | 173.6 ± 10.04 | 173.0 ± 10.26 | 173.3 ± 10.14 |
| Weight(kg) | CellCept + CNI (Tacrolimus or Cyclosporine) | CellCept + Sirolimus | Total |
|---|---|---|---|
| Mean | 79 ± 16.32 | 77.9 ± 17.56 | 78.4 ± 16.94 |
The record gives a start of Aug 2005, a primary completion of Jul 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tacrolimus · Cyclosporine